SCHEMBL27893247

SCHEMBL27893247

CCC(=O)OCCn1cncc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.45
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.36
EGFR P00533 5/20 0.35
ERBB2 P04626 5/20 0.35
MITF O75030 1/20 0.35
GUSB P08236 1/20 0.35
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11615550 0.86 GLA (0.47) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL11616957 0.80 SMN1; SMN2 (0.39) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL18366016 0.79 ALDH1A1 (0.50) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL11617013 0.78 LMNA (0.38) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL11616890 0.75 ALDH1A1 (0.36) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL5878432 0.75 LMNA (0.49) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL11618755 0.74 ALDH1A1 (0.43) ALDH1A1RAB9ASMN1; SMN2LMNAGAA
SCHEMBL28050025 0.73 ALDH1A1 (0.42) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL11581563 0.71 LMNA (0.56) GLAALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL16328893 0.71 LMNA (0.37) GLAALDH1A1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102958920-A Metronidazole esters for the treatment of rosacea GALDERMA RES & DEV 2013-03-06 CN disclosed